NJ State Employees Deferred Compensation Plan bought a new position in Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 4,000 shares of the biopharmaceutical company’s stock, valued at approximately $440,000. Several other hedge funds and other institutional […]
MetLife Investment Management LLC lifted its stake in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) by 4.9% in the 4th quarter, HoldingsChannel reports. The firm owned 18,318 shares of the biopharmaceutical company’s stock after buying an additional 854 shares during the quarter. MetLife Investment Management LLC’s holdings in Prometheus Biosciences were worth $2,015,000 […]
Prometheus Biosciences (NASDAQ:RXDX – Get Rating) had its price objective increased by Oppenheimer from $125.00 to $150.00 in a research note issued to investors on Wednesday morning, The Fly reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. Oppenheimer also issued estimates for Prometheus Biosciences’ Q1 2023 earnings at ($0.89) EPS, […]